Treatment with upadacitinib led to a significant reduction in disease activity for people with moderate-to-severe systemic lupus erythematosus (SLE)…
Articles by Marisa Wexler, MS
An enzyme called fumarate hydratase is involved in the control of the inflammatory activity of macrophages, a type of immune…
New measures are needed to assess disease severity in lupus in clinical trials, a study highlights. One important goal…
A urine test that can be performed at home showed good accuracy in detecting lupus nephritis, a form of…
The U.S. Patent and Trademark Office (USPTO) has allowed Aurinia Pharmaceuticals submit a new patented method of using Lupkynis…
The approvals of new medications in the last few years have dramatically shifted the treatment landscape for lupus nephritis, a…
Blocking CD71, a protein that cells use to import iron, reduced the disease-driving inflammatory activity of immune cells in preclinical…
Treatment with cenerimod showed promising trends toward reducing disease activity in systemic lupus erythematosus (SLE), especially in people with more…
Lupkynis (voclosporin) has been approved in Great Britain as a treatment for adults with active lupus nephritis by the…
The U.S. Food and Drug Administration (FDA) has agreed to allow Kyverna Therapeutics to begin clinical testing of KYV-101,…